Nurix appoints former Pfizer oncology chief Roger Dansey to board

Nurix Therapeutics, Inc.

Dr. Dansey appointed effective Nov 6, 2025, as Class III director and member of Clinical and Commercialization Committee.
Former Chief Development Officer and Chief Oncology Officer at Pfizer; previously CMO and interim CEO of Seagen.
Initial stock option grant of 50,000 shares, vesting monthly over three years; pro rata annual retainer of $50,000.
Dansey brings experience from leading Keytruda development at Merck and Xgeva at Amgen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.